Regulatory milestones

Labopharm Inc. (TSX:DDS; NASDAQ:DDSS) fell C$0.17 (14%) to C$1.05 in Toronto on Thursday after Health Canada delayed a decision on an NDS for once-daily trazodone to treat major depressive disorder (MDD) due to a backlog at the agency. The extended-release formulation of the serotonin antagonist reuptake inhibitor (SARI) is marketed as Oleptro in the U.S by Angelini Labopharm, a JV formed by Labopharm and Gruppo Angelini.

Labopharm was off C$0.15 (13%) to C$1.02 in Toronto for the week. On NASDAQ, the stock lost $0.18 (16%) to $0.97...